XLO - NASDAQ
Xilio Therapeutics, Inc.
$8.46
-0.71%Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
At a Glance
Live SnapshotXilio Therapeutics, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Xilio Therapeutics, Inc. Income Statement
XLO • NASDAQ
| Xilio Therapeutics, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
REVENUE | |||||||
43.8M | 6.3M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
GROSS PROFIT | |||||||
(1.5M) | (0.0) | (0.0) | (0.0) | (1.5M) | (1.1M) | (240K) | |
42.2M | 6.3M | 0.0 | 0.0 | -1.5M | -1.1M | -240K | |
OPERATING INCOME | |||||||
(84.2M) | (66.9M) | (79.1M) | (89.1M) | (73.5M) | (53.5M) | (18.8M) | |
(29.7M) | (24.8M) | (27M) | (29.9M) | (22.4M) | (9.6M) | (4.5M) | |
(56M) | (41.2M) | (52.1M) | (59.2M) | (51.2M) | (43.9M) | (14.3M) | |
-42M | -60.6M | -79.1M | -89.1M | -75M | -54.6M | -19M | |
PRE-TAX INCOME | |||||||
(0.0) | (100K) | (0.0) | (0.0) | (600K) | (600K) | (0.0) | |
3.4M | -100K | 0.0 | 0.0 | -599.4K | -599.4K | 0.0 | |
-1.5M | (937K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
6.9M | 2.3M | 2.7M | 927K | -756K | -656K | 1.7M | |
-35M | -58.2M | -76.4M | -88.2M | -75.8M | -55.2M | -17.3M | |
NET INCOME | |||||||
-35M | -58.2M | -76.4M | -88.2M | -75.8M | -55.2M | -17.3M |
SEC Filings
XLO - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
S-3/A S-3/A (Amended) N/A | May 27, 2026 | May 27, 2026 | ||
8-K 8-K 2026 N/A | May 12, 2026 | May 12, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 12, 2026 | March 31, 2026 | 2026 | |
S-3 S-3 N/A | May 12, 2026 | May 12, 2026 | ||
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | June 10, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 16, 2026 | April 15, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 23, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 23, 2026 | March 23, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 12, 2026 | March 12, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 09, 2026 | March 09, 2026 | 2026 |
Related Guides
Continue your XLO research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.